Armata Pharmaceuticals Joins H.C. Wainwright Global Investment Conference
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) is excited to announce its participation in the H.C. Wainwright 27th Annual Global Investment Conference. This important gathering is taking place in New York and is expected to attract a wide audience of investors, stakeholders, and industry experts.
Corporate Presentation Details
Deborah Birx, M.D., serves as the Chief Executive Officer of Armata and will lead the corporate presentation scheduled for September 10. Attendees can expect insights into Armata's latest developments in bacteriophage therapeutics, a pivotal area of focus for the company. Armata is at the forefront of tackling antibiotic-resistant infections through innovative technology.
Innovative Bacteriophage Therapeutics
At the heart of Armata's mission is the commitment to the development of high-purity, pathogen-specific bacteriophage therapeutics. These novel therapeutics aim to address the growing crisis of antibiotic-resistant infections effectively.
Pioneering Research and Development
Armata's research targets various challenging bacterial pathogens, including Pseudomonas aeruginosa and Staphylococcus aureus. Through rigorous clinical development, the company has been advancing a promising pipeline of both natural and synthetic phage candidates, demonstrating significant potential in revolutionizing infection management.
Engagement Opportunities at the Conference
During the conference, participants will have the chance to engage with Armata's representatives and learn more about the company’s innovative solutions. Those interested in one-on-one meetings can reach out to the H.C. Wainwright team to schedule discussions.
About Armata Pharmaceuticals
Armata Pharmaceuticals has established itself as a notable player in the biotechnology arena. With an unwavering dedication to tackling some of the toughest bacterial infections through phage therapy, the company leverages cutting-edge manufacturing practices to facilitate the development of its products. This includes adhering to current Good Manufacturing Practices throughout the research, development, and potential commercialization phases.
Contact Information
For Media Inquiries:
Pierre Kyme
310-594-7035
Investor Relations Contact:
Joyce Allaire
LifeSci Advisors, LLC
212-915-2569
Frequently Asked Questions
What is the purpose of the H.C. Wainwright conference?
The H.C. Wainwright conference brings together investors and companies to discuss upcoming innovations and strategies in the biotech industry.
Who is presenting for Armata Pharmaceuticals?
Deborah Birx, M.D., the Chief Executive Officer of Armata Pharmaceuticals, will lead the presentation at the conference.
What are bacteriophage therapeutics?
Bacteriophage therapeutics involve the use of viruses that specifically target and destroy bacterial pathogens, providing an innovative approach to treat infections.
What pathogens does Armata focus on?
Armata Pharmaceuticals concentrates its efforts on serious bacterial pathogens, particularly Pseudomonas aeruginosa and Staphylococcus aureus.
How can I schedule a meeting with Armata during the conference?
Interested individuals should contact their H.C. Wainwright representative to arrange one-on-one meetings with Armata Pharmaceuticals.
